Unveiling NLR pathway signatures: EP300 and CPN60 markers integrated with clinical data and machine learning for precision NASH diagnosis.

Journal: Cytokine
PMID:

Abstract

BACKGROUND: Given the increasing prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic steatohepatitis (NASH), there is a critical need for accurate non-invasive early diagnostic markers.

Authors

  • Marwa Matboli
    Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Noha E El-Attar
    Information Systems Department, Faculty of Computers and Artificial Intelligence, Banha University, Banha, Egypt. noha.ezzat@fci.bu.edu.eg.
  • Ibrahim Abdelbaky
    Department of Electronics and Information Engineering, Jeonbuk National University, Jeonju, 54896, South Korea.
  • Radwa Khaled
    Biotechnology/Biomolecular Chemistry Department, Faculty of Science, Cairo University, Cairo, Egypt.
  • Maha Saad
    Faculty of Medicine, Modern University for Technology and Information, Cairo, Egypt. Electronic address: maha.saad@medicine.mti.edu.eg.
  • Amani Mohamed Abdel Ghani
    Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt. Electronic address: dr_amani83@med.asu.edu.eg.
  • Eman Barakat
    Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: dreman_barakat96@medi.asu.edu.eg.
  • Reginia Nabil Mikhail Guirguis
    Department of Internal Medicine, Ain Shams University, Cairo, Egypt.
  • Eman Khairy
    Medical biochemistry and molecular biology department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt; Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah 23890, Saudi Arabia. Electronic address: dreman_khairy@med.asu.edu.eg.
  • Shaimaa Hamady
    Faculty of Science, Ain Shams University, Cairo, Egypt.